Luminex Acquires MilliporeSigma Flow Cytometry Portfolio
By Labmedica International staff writers
08 Jan 2019
Luminex Corporation (Austin, Texas, USA) has completed its previously announced acquisition of MilliporeSigma's (Burlington, MA, USA) flow cytometry portfolio.
Luminex offers a wide range of solutions applicable in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex's newly acquired flow cytometry portfolio includes the Amnis family of imaging flow cytometry products for cell-based analysis, as well as the Guava portfolio of systems based on microcapillary technologies.
"We are pleased to announce the completion of this transaction and excited to welcome the talented MilliporeSigma flow cytometry team to the Luminex family," said Homi Shamir, president and CEO of Luminex. "This acquisition enables us to enhance our existing offering of flow-based detection systems, while simultaneously expanding our direct interactions with researchers conducting cellular analysis."
"The Amnis and Guava products complement our wide range of existing flow-based offerings, further differentiating our portfolio and ensuring we are well-positioned to support customers today and into the future," said Shamir. "With this acquisition, we now have expanded our installed based to include more than 5,000 flow cytometry systems worldwide, adding to our impressive footprint and creating the potential for additional meaningful growth."